Table 2.
Trials evaluating the use of cetuximab with chemotherapy in relapsed/refractory in Stage IIIb/IV NSCLC
| Author | Phase | n | Treatment | Results |
|---|---|---|---|---|
| Hanna et al90 | II | 66 | Weekly cetuximab | ORR 4.5% Median OS 8.9 mos Median TTP 2.3 mos |
| Jalal et al91 | I/IIa | 23 | Weekly cetuximab + Pem (750 mg/m2 iv every 3 weeks) |
ORR 9.5% Median TTP 5.5 mos |
| Kim et al92 | II | 47 | Weekly cetuximab + Doc (75 mg/m2 iv every 3 weeks) |
Median TTP 89 days |
Abbreviations: OS, overall survival; TTP, time to progression; Pem, pemetrexed; ORR, overall response rate.